Business Description
Actuate Therapeutics Inc
NAICS : 541715
SIC : 2836
Description
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3?, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | -33.25 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 51.8 | |||||
9-Day RSI | 45.68 | |||||
14-Day RSI | 42.93 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.43 | |||||
Quick Ratio | 0.43 | |||||
Cash Ratio | 0.43 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -210.78 | |||||
ROIC % | -12182.44 | |||||
ROCE % | -404.5 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -6.42 | |||||
EV-to-EBITDA | -6.42 | |||||
EV-to-FCF | -7.34 | |||||
Earnings Yield (Greenblatt) % | -15.58 | |||||
FCF Yield % | -13.88 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ACTU
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Actuate Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -1.65 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 42.93 | ||
14-Day ATR ($) | 0.617888 | ||
20-Day SMA ($) | 0 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range ($) | 7.33 - 10.162 | ||
Shares Outstanding (Mil) | 19.11 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Actuate Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Actuate Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Actuate Therapeutics Inc Frequently Asked Questions
What is Actuate Therapeutics Inc(ACTU)'s stock price today?
The current price of ACTU is $8.15. The 52 week high of ACTU is $10.16 and 52 week low is $7.33.
When is next earnings date of Actuate Therapeutics Inc(ACTU)?
The next earnings date of Actuate Therapeutics Inc(ACTU) is .
Does Actuate Therapeutics Inc(ACTU) pay dividends? If so, how much?
Actuate Therapeutics Inc(ACTU) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |